The relative prevalence of these malignant states was then translated into an eight−gene expression signature derived from the GPRC5A+ program that stratifies patients into high− and low−risk groups with distinct tumor microenvironments and predicted drug sensitivities. Here, GPRC5A is linked to neoplasm.